醫思健康(02138.HK):預計第三財季整體銷售額不少於8.8億港元 同比升幅不少於41%
格隆匯1月10日丨醫思健康(02138.HK)發佈公吿,2021年10月1日至12月31日期間,集團預期錄得季內整體銷售額不少於8.8億港元,較去年同期升幅不少於41%,及較2019年同期升幅不少於64%;季內中國內地診所以及服務中心的銷售額較去年同期升幅不少於13%,及較2019年同期升幅不少於65%;及季內集團所提供的醫療服務銷售額較去年同期增長不少於51%,及較2019年同期升幅不少於158%。
公吿表示,該增長主要是由於新型冠狀病毒疫情爆發後健康管理意識的普遍提升,而對集團提供的醫療服務的需求維持強勁;隨着疫情受控以及中國香港政府推出消費券計劃,本地消費情緒改善及零售業全面復甦;及因截至2022年3月31日止財政年度上半年收購醫療資產而產生的正面協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.